Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.61 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | SMO | Q99835 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 6/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988789 | 0.87 | ALOX5AP (0.59) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL2996703 | 0.87 | ALOX5AP (0.59) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL3000978 | 0.86 | ALOX5AP (0.58) | ALOX5APADAMTS4PARP10KDM4EALDH1A1 | |
| SCHEMBL3001136 | 0.86 | ALOX5AP (0.60) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL2990888 | 0.86 | ALOX5AP (0.60) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL2997610 | 0.86 | ALOX5AP (0.57) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL2999071 | 0.85 | ALOX5AP (0.59) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL2996699 | 0.84 | ALOX5AP (0.58) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL3002224 | 0.84 | ALOX5AP (0.59) | ALOX5APADAMTS4PARP10MAPK14SMO | |
| SCHEMBL2991626 | 0.83 | ALOX5AP (0.61) | ALOX5APADAMTS4PARP10MAPK14SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | ALOX5AP 15/4885ADAMTS4 1336/4885PARP10 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.